亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Generation Natural Killer Cell-Mimic Nanoparticles for Active Targeting of Acute Myeloid Leukemia

髓系白血病 白血病 髓样 癌症研究 免疫学 医学
作者
Hojjat Alizadeh Zeinabad,Wen Jie Yeoh,Philippe Krebs,Carsten Riether,Mihai Lomora,Yara Banz,Éva Szegezdi
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 10682-10683
标识
DOI:10.1182/blood-2022-166893
摘要

Natural killer (NK) cells play a crucial role in recognizing and killing emerging tumor cells. Via an array of activating and inhibitory receptors, NK cells can target and kill abnormal cells, including tumor cells, without prior antigen sensitization. However, fully-established tumors employ numerous mechanisms to inactivate NK cells or hide from them, for example by shedding NK cell-activating ligands, like NK2GD (Chiossone et al., 2018). Here, we describe the engineering of nanoparticles (NPs) functionalized with tumor-recognizing and cytotoxic components of NK cells to address this problem and develop a nanoparticle-based treatment strategy simulating NK cell functionality. Liposomes were synthesized using the thin film hydration method followed by extrusion and functionalized them with the death ligand, TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), immunoglobulin Fc-binding peptide (FCP, replicating the function of NK CD16 receptor) and the therapeutic antibody, anti-CD38 (daratumumab, Panel A) to target acute myeloid leukemia (AML). Transmission electron microscopy (TEM) and dynamic light scattering (DLS) were used to monitor morphology and size of liposomes. The potential of NK cell-mimic NPs (CD38-NK.NPs) to target and kill AML cells was evaluated on primary AML blasts and a disseminated AML xenograft for which the CD38-positive AML cell line, OCI-AML2 was engrafted into 8-9 week-old female NSG mice. Upon establishment of AML, the mice were injected intraperitoneally (i.p) with 5 doses of either naked liposomes (as vehicle control), soluble TRAIL protein (sTRAIL), LP/TRAIL or CD38-NK.NPs every two days. Tumor burden was monitored by determining the frequency of live human CD45+ cells in the peripheral blood, spleen and bone marrow with flow cytometry. Liposome was chosen as the base of the NP due to its high biocompatibility, biodegradability, cell-like characteristics and capability to penetrate through vessel walls (Pattni, Chupin and Torchilin, 2015). TEM and DLS measurements showed the generated NK.NPs were monodisperse with an average diameter of 145 nm, a size enabling vessel transmigration and avoiding kidney filtration (Gaumet et al., 2008). Immunofluorescent labelling of TRAIL, FCP and antibody verified CD38-NK.NPs functionalization. In vitro, both TRAIL-conjugated liposomes and CD38-NK.NPs were more effective in killing AML cell lines (ML-1, ML-2, Kasumi-1, and OCI-AML2) than sTRAIL, indicating that TRAIL-mediated cytotoxicity can be enhanced by presenting TRAIL in a conformation close to its membrane-bound structure. No significant difference could be detected between LP/TRAIL vs. CD38-NK.NP cytotoxicity in the in vitro assays. On the other hand, CD38-NK.NPs were more effective in killing primary AML blasts than non-targeted, NP-conjugated TRAIL (LP/TRAIL, 13±17% vs 4±15% killing, respectively). Moreover, CD38-NK.NPs showed considerably higher activity relative to the NK cell line, KHYG-1, against CD38-positive AML cell lines. Notably, CD38-NK.NPs showed no significant cytotoxic effect on non-malignant peripheral blood leukocytes. In vivo, NK cell-mimic NPs were more efficient in targeting and eradicating CD38-positive AML cells that either sTRAIL or LP/TRAIL, shown by the reduced percentage of circulating hCD45+ AML cells in treated mice (Panel B). CD38-NK.NPs were also more efficient in inhibiting accumulation of AML cells in the bone and spleen than sTRAIL and LP/TRAIL (Panel B), confirming the ability of CD38-NK.NPs to actively target AML cells expressing the targeted biomarker. Of note, CD38-NK.NPs showed no detectable systemic toxicity or damage to kidneys, liver and pancreas in healthy NSG mice. Overall, we have developed an NK cell-mimic nanoparticle able to actively target AML based on AML surface marker expression without any detectable systematic toxicity. Importantly, due to the modular built of the NK.NPs, they can be functionalized by any therapeutic tumor-targeting antibody via the immunoglobulin-binding peptide (FCP), thus enabling selective targeting tumor cells based on expression of tumor-specific markers and enabling personalized therapy. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
悦耳的沛岚完成签到,获得积分10
1秒前
4秒前
Xiaowen发布了新的文献求助10
4秒前
123发布了新的文献求助10
9秒前
学习使人头大完成签到 ,获得积分10
11秒前
jyy应助坚定灯泡采纳,获得10
13秒前
16秒前
3080完成签到 ,获得积分10
18秒前
小芭乐完成签到 ,获得积分10
19秒前
23秒前
25秒前
25秒前
sunshihaoya发布了新的文献求助10
27秒前
占那个完成签到 ,获得积分10
28秒前
cos发布了新的文献求助10
30秒前
Bond完成签到 ,获得积分10
31秒前
33秒前
852应助sunshihaoya采纳,获得10
38秒前
41秒前
辉哥发布了新的文献求助10
43秒前
碳酸芙兰完成签到,获得积分10
45秒前
fox完成签到 ,获得积分10
46秒前
烟花应助辉哥采纳,获得10
49秒前
58秒前
科研通AI5应助王梦豪采纳,获得10
59秒前
隐形曼青应助感性的送终采纳,获得10
1分钟前
cos完成签到,获得积分10
1分钟前
甜心糖完成签到 ,获得积分10
1分钟前
shuhaha完成签到,获得积分10
1分钟前
李健的小迷弟应助wlei采纳,获得10
1分钟前
1分钟前
大恐龙的噗噗完成签到,获得积分10
1分钟前
1分钟前
CodeCraft应助小余同学采纳,获得10
1分钟前
徐志豪发布了新的文献求助10
1分钟前
nnnick完成签到,获得积分0
1分钟前
Aurora发布了新的文献求助10
1分钟前
1分钟前
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976600
求助须知:如何正确求助?哪些是违规求助? 3520700
关于积分的说明 11204482
捐赠科研通 3257320
什么是DOI,文献DOI怎么找? 1798683
邀请新用户注册赠送积分活动 877881
科研通“疑难数据库(出版商)”最低求助积分说明 806613